NSAIDs are among the most widely used and prescribed drugs in the U.S. This class contains approximately 20 drugs that share inhibition of the cyclooxygenase enzyme as a mechanism of action. Although this class also contains acetaminophen and salicylates, these two drugs possess unique toxicity and are considered in separate chapters (see Chapter 183, Aspirin and Salicylates, and Chapter 184, Acetaminophen). NSAIDs are effective antipyretics, analgesics, and anti-inflammatory agents. Because of their large therapeutic window, NSAIDs are relatively safe agents with respect to acute ingestion and overdose, rarely producing serious complications.1–3 Several agents are now available without prescription (over the counter), and the world sales for NSAIDs is reported to be $6 billion per year in U.S. dollars.4


During 2008, the American Association of Poison Control Centers received reports of 107,115 NSAID exposures (excluding aspirin and acetaminophen) resulting in 65 (0.05%) major outcomes (life-threatening signs and symptoms or significant residual disability).5 There were 44 deaths where NSAIDs were mentioned and 5 deaths associated with single exposure. This experience compares favorably with the toxicity reported with isolated aspirin or acetaminophen ingestions during 2008: 99,210 exposures with 84 deaths.5 It should be remembered that poison center data are gathered passively and likely underrepresent the true number of exposed persons. The morbidity from NSAIDs in acute overdose is far overshadowed by complications of NSAIDs at therapeutic doses, including GI bleeding, drug-induced renal failure, and ischemic heart disease.6–8 Due to an increased risk for cardiovascular disease with therapeutic doses, the selective cyclooxygenase-2 inhibitors rofecoxib and valdecoxib were withdrawn from the U.S. market in 2004 and 2005, respectively.




NSAIDs are structurally varied compounds with common therapeutic effects (Table 185-1). With the exception of aspirin and other salicylates, NSAIDs reversibly inhibit the enzyme cyclooxygenase, which is responsible for the production of prostaglandins from arachidonic acid (Figure 185-1). The anti-inflammatory effect of NSAIDs is through the inhibition of prostaglandin production, but they may also inhibit neutrophils via mechanisms unrelated to prostaglandin. NSAIDs work as antipyretics through inhibition of prostaglandin E2 in the hypothalamus. NSAIDs also appear to attenuate prostaglandin-mediated hyperalgesia and local pain fiber stimulus.

Table Graphic Jump Location
Table 185-1 Classes of Nonsteroidal Agents Available in the U.S. 

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessMedicine Full Site: One-Year Subscription

Connect to the full suite of AccessMedicine content and resources including more than 250 examination and procedural videos, patient safety modules, an extensive drug database, Q&A, Case Files, and more.

$995 USD
Buy Now

Pay Per View: Timed Access to all of AccessMedicine

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.